Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2010 1
2011 1
2012 1
2015 3
2016 1
2017 1
2018 1
2020 6
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
Portaccio E, Fonderico M, Iaffaldano P, Pastò L, Razzolini L, Bellinvia A, De Luca G, Ragonese P, Patti F, Brescia Morra V, Cocco E, Sola P, Inglese M, Lus G, Pozzilli C, Maimone D, Lugaresi A, Gazzola P, Comi G, Pesci I, Spitaleri D, Rezzonico M, Vianello M, Avolio C, Logullo FO, Granella F, Salvetti M, Zaffaroni M, Lucisano G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register Centers Group. Portaccio E, et al. JAMA Neurol. 2022 Sep 1;79(9):869-878. doi: 10.1001/jamaneurol.2022.1929. JAMA Neurol. 2022. PMID: 35877104 Free PMC article. Clinical Trial.
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, Bellinvia A, Tudisco L, Fratangelo R, Comi G, Patti F, De Luca G, Brescia Morra V, Cocco E, Pozzilli C, Sola P, Bergamaschi R, Salemi G, Inglese M, Millefiorini E, Galgani S, Zaffaroni M, Ghezzi A, Salvetti M, Lus G, Florio C, Totaro R, Granella F, Vianello M, Gatto M, Di Battista G, Aguglia U, Logullo FO, Simone M, Lucisano G, Iaffaldano P, Trojano M. Amato MP, et al. Among authors: florio c. Brain. 2020 Oct 1;143(10):3013-3024. doi: 10.1093/brain/awaa251. Brain. 2020. PMID: 32935843
GABAA receptor autoimmunity after alemtuzumab treatment for multiple sclerosis.
Maniscalco GT, Mariotto S, Höftberger R, Capra R, Servillo G, Manzo V, Napolitano M, Candelaresi P, Gerevini S, Ferrari S, Bozzetti S, Spatola M, Florio C. Maniscalco GT, et al. Among authors: florio c. Neurology. 2020 Sep 1;95(9):399-401. doi: 10.1212/WNL.0000000000010310. Epub 2020 Jul 10. Neurology. 2020. PMID: 32651290 No abstract available.
Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project.
Maniscalco GT, Brescia Morra V, Florio C, Lus G, Tedeschi G, Cianfrani M, Docimo R, Miniello S, Romano F, Sinisi L, Spitaleri DLA, Longo G, Trama U, Triassi M, Fasm Group, Scavone C, Capuano A. Maniscalco GT, et al. Among authors: florio c. Pharmaceuticals (Basel). 2020 Dec 15;13(12):466. doi: 10.3390/ph13120466. Pharmaceuticals (Basel). 2020. PMID: 33333889 Free PMC article.
KIRs and their HLA ligands in remitting-relapsing multiple sclerosis.
Fusco C, Guerini FR, Nocera G, Ventrella G, Caputo D, Valentino MA, Agliardi C, Gallotti J, Morra VB, Florio C, Clerici M, Lombardi ML. Fusco C, et al. Among authors: florio c. J Neuroimmunol. 2010 Dec 15;229(1-2):232-7. doi: 10.1016/j.jneuroim.2010.08.004. Epub 2010 Sep 9. J Neuroimmunol. 2010. PMID: 20826009
One year experience with erenumab: real-life data in 30 consecutive patients.
Ranieri A, Alfieri G, Napolitano M, Servillo G, Candelaresi P, Di Iorio W, Longo K, Maniscalco GT, Renna R, Rippa M, Salvatore S, Sagnelli A, Florio C, Manzo V. Ranieri A, et al. Among authors: florio c. Neurol Sci. 2020 Dec;41(Suppl 2):505-506. doi: 10.1007/s10072-020-04677-y. Neurol Sci. 2020. PMID: 32845486 No abstract available.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Carrieri PB, Carbone F, Perna F, Bruzzese D, La Rocca C, Galgani M, Montella S, Petracca M, Florio C, Maniscalco GT, Spitaleri DL, Iuliano G, Tedeschi G, Della Corte M, Bonavita S, Matarese G. Carrieri PB, et al. Among authors: florio c. Metabolism. 2015 Sep;64(9):1112-21. doi: 10.1016/j.metabol.2015.05.001. Epub 2015 May 8. Metabolism. 2015. PMID: 25986733
17 results